NASDAQ: KLRA

Kailera Therapeutics, Inc.

CIK 0002096997 · Pharmaceutical Preparations

Mid by assets Assets $625M as of Jul 5, 2026

Each report below shows a 3-bullet preview. Free accounts read 3 full reports a month — narrative summary, section diffs, and EDGAR-cited quotes.

Want to see a complete report first? Today's free report (ADMT 10-K) is open in full — no account needed.

10-Q Filed May 26, 2026 · Period ending Mar 31, 2026

Kailera debuts Q1 2026: $79M loss, $582M cash, IPO adds $719M runway into mid-2028

5 material changes detected. Sign up free to read the summary.

View report

8-K Filed May 26, 2026 · Period ending May 26, 2026

1 material change detected. Sign up free to read the summary.

View report

Partner

Trade KLRA commission-free

Open an account, get a free stock.

Investing involves risk. Free stock terms apply.

8-K Filed Apr 20, 2026 · Period ending Apr 20, 2026

4 material changes detected. Sign up free to read the summary.

View report